NO20034323D0 - Medisinske aerosolformuleringer - Google Patents

Medisinske aerosolformuleringer

Info

Publication number
NO20034323D0
NO20034323D0 NO20034323A NO20034323A NO20034323D0 NO 20034323 D0 NO20034323 D0 NO 20034323D0 NO 20034323 A NO20034323 A NO 20034323A NO 20034323 A NO20034323 A NO 20034323A NO 20034323 D0 NO20034323 D0 NO 20034323D0
Authority
NO
Norway
Prior art keywords
aerosol formulations
salts
medical aerosol
medical
dosing
Prior art date
Application number
NO20034323A
Other languages
English (en)
Other versions
NO332848B1 (no
NO20034323L (no
Inventor
Rudi Mueller-Walz
Carsten Niederlaender
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of NO20034323D0 publication Critical patent/NO20034323D0/no
Publication of NO20034323L publication Critical patent/NO20034323L/no
Publication of NO332848B1 publication Critical patent/NO332848B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20034323A 2001-03-30 2003-09-26 Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer. NO332848B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH6012001 2001-03-30
CH15272001 2001-08-20
PCT/CH2002/000145 WO2002078671A1 (de) 2001-03-30 2002-03-11 Medizinische aerosolformulierungen

Publications (3)

Publication Number Publication Date
NO20034323D0 true NO20034323D0 (no) 2003-09-26
NO20034323L NO20034323L (no) 2003-09-26
NO332848B1 NO332848B1 (no) 2013-01-21

Family

ID=25737693

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034323A NO332848B1 (no) 2001-03-30 2003-09-26 Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer.

Country Status (23)

Country Link
US (1) US20040101483A1 (no)
EP (1) EP1372608B1 (no)
JP (1) JP4824267B2 (no)
CN (1) CN100496608C (no)
AT (1) ATE375142T1 (no)
AU (1) AU2002234476B2 (no)
CA (1) CA2442415C (no)
CY (1) CY1107128T1 (no)
CZ (1) CZ301676B6 (no)
DE (1) DE50211045D1 (no)
DK (1) DK1372608T3 (no)
ES (1) ES2292713T3 (no)
HK (1) HK1064295A1 (no)
HU (1) HU229798B1 (no)
NO (1) NO332848B1 (no)
NZ (1) NZ528640A (no)
PL (1) PL207377B1 (no)
PT (1) PT1372608E (no)
RO (1) RO121172B1 (no)
RU (1) RU2294737C2 (no)
SK (1) SK286394B6 (no)
WO (1) WO2002078671A1 (no)
ZA (1) ZA200307161B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
EP1487417A4 (en) 2001-09-17 2010-03-17 Glaxo Group Ltd DRY POWDER DRUG FORMULATIONS
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
AU2003295695B2 (en) * 2002-12-10 2009-08-20 Sepracor Inc. Levalbuterol salt
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
JP2009514779A (ja) * 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
WO2005074918A1 (en) 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
PL1713471T3 (pl) 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
JP4991693B2 (ja) 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
WO2007058971A2 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic esters
JP5107933B2 (ja) 2005-12-21 2012-12-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 炎症性疾患の治療に使用する、抗コリン作用薬類、β２−アドレナリン受容体のアゴニスト類、抗ロイコトリエン（ロイコトリエン受容体のアンタゴニスト）類、グルココルチコイド類および／またはＰＤＥ４阻害剤類の新規配合薬
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
TWI695723B (zh) * 2009-05-29 2020-06-11 美商沛爾醫療股份有限公司 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
AU2015201864A1 (en) * 2009-05-29 2015-04-30 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
UA113832C2 (xx) 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
PE20121467A1 (es) 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
KR20120106753A (ko) * 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
JP5513177B2 (ja) * 2010-03-08 2014-06-04 共同印刷株式会社 湿度インジケータとその製造方法、該製造方法に用いる湿度インジケータ用塗料
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
CA2850084C (en) * 2011-10-11 2020-07-07 Chiesi Farmaceutici S.P.A. Crystalline microparticles of a beta-agonist coated with a fatty acid
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
KR20180128450A (ko) * 2016-04-11 2018-12-03 수벤 라이프 사이언시스 리미티드 글리코피롤레이트의 국소 스프레이 포뮬레이션

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55361B1 (no) * 1970-09-17 1980-01-08
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
EP0561166A1 (de) * 1992-03-17 1993-09-22 ASTA Medica Aktiengesellschaft Dosieraerosole enthaltend den Wirkstoff D-18024 und verwandte Strukturen
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
JPH06135815A (ja) * 1992-10-30 1994-05-17 Shiseido Co Ltd 経皮吸収抑制組成物
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
DE4321288A1 (de) * 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
ES2193186T3 (es) * 1993-12-02 2003-11-01 Abbott Lab Composiciones medicamentosas en aerosol para la utilizacion con gases propulsores sin cfc.
US5589156A (en) * 1994-05-02 1996-12-31 Henry; Richard A. Prilocaine and hydrofluourocarbon aerosol preparations
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
JP3707107B2 (ja) * 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6261472B1 (en) * 1996-11-04 2001-07-17 E. I. Du Pont De Nemours And Company Azeotrope-like compositions containing fluoroethane
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
JP2001509801A (ja) * 1997-01-30 2001-07-24 アルペンストック・ホールディングス・リミテッド 組成物
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DE59911149D1 (de) * 1998-07-24 2004-12-30 Jago Res Ag Muttenz Medizinische aerosolformulierungen
PT1102579E (pt) * 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
ME00220B (me) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
DK2283818T3 (en) * 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
ATE465712T1 (de) * 2002-03-01 2010-05-15 Chiesi Farma Spa Ultrafeine zusammensetzungen von formoterol
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation

Also Published As

Publication number Publication date
HK1064295A1 (en) 2005-01-28
US20040101483A1 (en) 2004-05-27
DE50211045D1 (de) 2007-11-22
SK13342003A3 (sk) 2004-08-03
ZA200307161B (en) 2005-01-26
EP1372608B1 (de) 2007-10-10
CN100496608C (zh) 2009-06-10
NO332848B1 (no) 2013-01-21
HU229798B1 (en) 2014-07-28
JP4824267B2 (ja) 2011-11-30
ATE375142T1 (de) 2007-10-15
RO121172B1 (ro) 2007-01-30
JP2004525148A (ja) 2004-08-19
PL207377B1 (pl) 2010-12-31
NO20034323L (no) 2003-09-26
DK1372608T3 (da) 2007-12-27
RU2294737C2 (ru) 2007-03-10
CN1499958A (zh) 2004-05-26
CA2442415C (en) 2010-07-20
SK286394B6 (sk) 2008-09-05
HUP0401250A2 (hu) 2004-11-29
AU2002234476C1 (en) 2002-10-15
RU2003131676A (ru) 2005-02-10
HUP0401250A3 (en) 2008-04-28
PT1372608E (pt) 2008-01-04
PL362797A1 (en) 2004-11-02
CY1107128T1 (el) 2012-10-24
EP1372608A1 (de) 2004-01-02
CZ20032915A3 (en) 2004-06-16
WO2002078671A1 (de) 2002-10-10
NZ528640A (en) 2004-06-25
CZ301676B6 (cs) 2010-05-19
AU2002234476B2 (en) 2006-04-27
CA2442415A1 (en) 2002-10-10
ES2292713T3 (es) 2008-03-16

Similar Documents

Publication Publication Date Title
DK1372608T3 (da) Medicinske aerosolformuleringer
ATE373422T1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
NO20010531D0 (no) Medisinske aerosolformuleringer
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
DE60207198D1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
HUP0202243A2 (hu) Ketotiféntartalmú szemészeti készítmény
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
DE60101486D1 (de) Verwendung von Polyaminosäurederivate als Konservierungsmittel
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
BR0207725A (pt) Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos
UY27373A1 (es) Formulaciones de interferón beta-humano
ITMI20022549A1 (it) Composizione quaternaria comprendente come sostanza attiva la propolis.
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
DE60033416D1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
BRPI0507144A (pt) formulações em pó

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees